This technical reference evaluates the pricing factors, structural biology, and preclinical literature surrounding Cortagen (Ala-Glu-Asp-Pro) in cardiac gene expression research. Written for laboratory principal investigators and analytical researchers, this guide examines peptide purity metrics, epigenetic mechanisms, and institutional procurement standards.
This technical reference evaluates the pricing factors, structural biology, and preclinical literature surrounding Cortagen (Ala-Glu-Asp-Pro) in cardiac gene expression research. Written for laboratory principal investigators and analytical researchers, this guide examines peptide purity metrics, epigenetic mechanisms, and institutional procurement standards.
Research-grade Cortagen (Ala-Glu-Asp-Pro) pricing reflects its analytical purity (≥98%), manufacturing origin, and third-party verification, typically evaluated per milligram for laboratory assays. In preclinical models, Cortagen is investigated for its capacity to modulate cardiac gene expression, histone modifications, and peptide-DNA chromatin interactions without clinical or human therapeutic applications.
When purchasing Cortagen peptide for laboratory experimentation, cost variation across suppliers is primarily driven by synthesis methods, purification steps, and analytical verification quality. High-purity synthetic tetrapeptides require solid-phase peptide synthesis (SPPS) combined with reverse-phase high-performance liquid chromatography (RP-HPLC) to remove truncated sequences and residual organic solvents. Lower-priced alternatives often omit rigorous lot-specific analytical verification, such as Electrospray Ionization Mass Spectrometry (ESI-MS) or Limulus Amebocyte Lysate (LAL) endotoxin quantification. For robust, reproducible transcriptomic data in cardiac cell lines or animal models, investigators prioritize validated purity metrics over unverified, low-cost raw materials.
Cortagen is a synthetic bioregulatory tetrapeptide comprising the amino acid sequence L-Alanyl-L-glutamyl-L-aspartyl-L-proline (H-Ala-Glu-Asp-Pro-OH). It has a molecular weight of approximately 418.4 g/mol. Derived from short-chain peptide research initially established by Russian bioregulation scientists, Cortagen belongs to a specialized class of synthetic peptide mimetics engineered to penetrate cellular membranes and interact directly with nucleosomal DNA.
The primary structural feature of Cortagen is its amphipathic nature and net negative charge at physiological pH, conferred by the side-chain carboxyl groups of glutamic acid and aspartic acid. This carboxyl density, paired with the rigid proline C-terminus, allows the molecule to adopt stable spatial conformations. These conformations facilitate specific electrostatic binding to the major and minor grooves of double-stranded DNA, as well as regulatory histone proteins within the chromatin architecture.
The primary mechanism of action explored in cortagen gene expression mechanisms involves direct and indirect epigenetic modulation. In vitro studies using cultured cardiomyocytes indicate that short synthetic tetrapeptides can cross nuclear membranes without dedicated transport receptors, directly associating with histone tails and specific promoter sequences of targeted genes.
Preclinical investigations demonstrate that Cortagen administration in experimental systems alters the transcriptional profile of genes encoding antioxidant enzymes, structural cardiac proteins, and inflammatory cytokines. By promoting chromatin decompaction (euchromatin formation) around specific gene loci, Cortagen facilitates the binding of RNA polymerase II and transcription factors. In cardiac tissue models, this epigenetic remodeling is observed to upregulate endogenous protective pathways, including superoxide dismutase (SOD1/SOD2) and heat shock proteins (HSP70), while downregulating pro-inflammatory markers such as nuclear factor kappa B (NF-κB).
Preclinical studies evaluating Cortagen in rodent models of myocardial ischemia-reperfusion injury show a significant attenuation of necrotic cell death and tissue remodeling. In these experimental designs, subjects treated with research-grade Cortagen exhibited altered expression of apoptotic cascades—specifically a decreased Bax/Bcl-2 ratio—which preserved mitochondrial membrane integrity in hypoxic cardiomyocytes.
In vitro data from isolated vascular endothelial cell cultures and myocardial tissue explants further indicate that Cortagen modulates extracellular matrix (ECM) gene expression. Researchers have documented shifts in matrix metalloproteinase (MMP-2 and MMP-9) transcript levels alongside tissue inhibitors of metalloproteinases (TIMP-1), suggesting a regulatory role in cardiac structural maintenance post-ischemic insult. These findings positions Cortagen as a valuable tool for investigating transcriptomic responses to oxidative stress and mechanical overload in cardiovascular biology.
To understand the relative position of Cortagen within bioregulatory peptide research, laboratory investigators frequently compare its activity, sequence length, and gene targets against other short synthetic peptides. The table below delineates key structural and mechanistic distinctions among prominent compounds in this class.
In experimental models of tissue maintenance and genomic stability, Cortagen is evaluated alongside short synthetic analogs such as Epitalon, which targets telomerase reverse transcriptase (TERT) gene expression, and Vilon, a dipeptide investigated for immune-system gene modulation. While BPC-157 is extensively studied in growth factor gene expression and focal adhesion kinase pathways, Cortagen specifically targets nuclear chromatin interactions relevant to cardiovascular and central nervous system transcriptomics. Comparing these compounds in parallel assays allows research teams to map distinct structural requirements for specific epigenetic outcomes.
When evaluating the commercial price of Cortagen, researchers must assess the underlying analytical quality documentation provided by the manufacturer. High-purity research compounds must undergo comprehensive quality control to ensure that observed cellular responses are attributable solely to the active tetrapeptide sequence and not to synthetic impurities or bacterial endotoxins.
PX1 Research enforces strict testing criteria for every lot of Cortagen, utilizing an ISO 17025 accredited laboratory infrastructure:
• High-Performance Liquid Chromatography (RP-HPLC): Confirms chemical purity ≥98%, ensuring the absence of deletion sequences or truncated peptides. • Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact molecular weight (418.4 g/mol) and identity. • Endotoxin Testing (LAL Assay): Guarantees endotoxin levels <0.01 EU/mg, preventing false-positive inflammatory responses in cell culture assays. • Residual Solvent & Heavy Metal Analysis: Ensures complete removal of trifluoroacetic acid (TFA) salts, acetonitrile, and heavy metals post-synthesis.
Proper handling and reconstitution protocols are critical to maintaining the chemical stability and biological activity of Cortagen in laboratory settings. Cortagen is supplied as a lyophilized (freeze-dried) powder under vacuum or inert gas atmosphere. For detailed volumetric calculations, researchers should consult our peptide reconstitution calculator.
Upon arrival, lyophilized Cortagen should be stored at -20°C or -80°C in a desiccated environment, shielded from light. Reconstitution should be performed using sterile Bacteriostatic Water, sterile normal saline (0.9% NaCl), or phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the downstream assay. After addition of the solvent, gentle swirling is recommended; vortexing should be minimized to prevent mechanical shear stress. Reconstituted stock solutions should be divided into single-use aliquots and frozen at -80°C to avoid repetitive freeze-thaw cycles, which can cause peptide bond degradation.
The overall pricing for research-grade Cortagen varies based on scale, purity specification, and verification standards. While raw, unverified custom peptides can be procured at lower initial costs, the lack of third-party verification introduces substantial risk of batch-to-batch variation, cytotoxic solvent contamination, and misleading gene expression assay results.
Evaluating supplier pricing requires looking beyond the base cost per vial to consider total quality assurance. Premium research suppliers like PX1 Research manufacture peptides in US-based, GMP-compliant facilities and provide lot-specific Certificate of Analysis (COA) documentation with every order. This ensures that academic and industrial laboratories receive verified, highly reproducible reagents suitable for advanced transcriptomic and genomic studies across our complete peptide catalog.
For high-throughput screening, multi-center studies, or longitudinal animal research projects, institutional procurement departments require consistent batch sizes and guaranteed supply continuity. Variations in peptide lot characteristics mid-study can compromise entire experimental datasets, necessitating costly repeat trials.
PX1 Research supports university research groups, contract research organizations (CROs), and biotechnology firms through dedicated bulk supply pipelines. Operating out of dual fulfillment centers in California and Arizona, PX1 offers same-day dispatch for stock items, complete lot traceability, and volume-based pricing structures for institutional accounts. Research teams planning large-scale cardiac gene expression studies can request quotes and establish custom synthesis agreements through our wholesale research portal.
What factors determine the price of research-grade Cortagen for cardiac gene expression studies?
Cortagen pricing is determined by synthesis scale, purity level (≥98% standard), solid-phase purification efficiency, and third-party analytical verification (RP-HPLC, ESI-MS, and LAL endotoxin testing).
What is the molecular structure and sequence of Cortagen?
Cortagen is a synthetic bioregulatory tetrapeptide with the amino acid sequence L-Alanyl-L-glutamyl-L-aspartyl-L-proline (Ala-Glu-Asp-Pro), with a molecular weight of approximately 418.4 g/mol.
How does Cortagen influence cardiac gene expression in preclinical models?
Preclinical studies indicate that Cortagen interacts directly with nuclear chromatin, inducing epigenetic modifications that modulate the transcription of stress-response genes, antioxidant enzymes (SOD1/2), and inflammatory cascades (NF-κB).
Is Cortagen approved for clinical or human therapeutic use?
No. Cortagen is strictly a research-grade compound intended exclusively for in vitro laboratory assays and animal research. It is not approved for human consumption, therapeutic use, or medical treatment.
What quality control documentation should accompany Cortagen purchases?
Every lot of Cortagen should be accompanied by a lot-specific Certificate of Analysis (COA) verifying ≥98% purity via RP-HPLC, correct molecular identity via ESI-MS, and low endotoxin levels (<0.01 EU/mg).
How should Cortagen stock solutions be prepared and stored?
Lyophilized Cortagen should be stored at -20°C or -80°C. Reconstitution should be performed using sterile PBS or Bacteriostatic Water, followed by aliquoting and storage at -80°C to prevent freeze-thaw degradation.
How does Cortagen differ from Epitalon in epigenetic research?
While both are short bioregulatory synthetic peptides, Cortagen (Ala-Glu-Asp-Pro) primarily targets cardiac and neural tissue transcriptomics, whereas Epitalon (Ala-Glu-Asp-Gly) focuses on telomerase enzyme modulation and circadian gene expression.
Why is endotoxin testing critical for Cortagen used in cell culture?
Bacterial endotoxins (LPS) can stimulate immune receptor pathways in cultured cells, causing false gene expression changes. Low endotoxin levels (<0.01 EU/mg) ensure observed effects are directly attributable to Cortagen.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.